Drug regulator CDSCO and the National Regulatory Authority of India have met the standards set up by the World Health Organisation for a functional vaccine regulatory system
A team of international experts from various countries led by the World Health Organisation (WHO) headquarters in Geneva reviewed India's vaccine regulatory system from September 16 to 20, the health ministry said in a statement.
Safety, efficacy, and quality were the three basic parameters of assessment of vaccines, it said.
The WHO has established global standards and benchmarks for assurance of vaccine quality through the development of tools and guidelines, benchmarking of the National Regulatory Authorities (NRA) and pre-qualification programme of vaccines, the statement said.
The WHO NRA re-benchmarking was aimed to assess and document the status of the India regulatory system in the area of vaccine regulation, re-benchmark the status of the India vaccine regulatory system against the WHO NRA Global Benchmarking Tool (GBT) and measuring the maturity of the system.
"India has been declared 'functional' against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI. India's vaccine regulatory system was benchmarked in 2017 against Global benchmarking tool (GBT) version V which is now revised to GBT VI with raised bars and stringency in bench-marking criteria," the statement said.
India retains maturity level 3 with highest marks in several functions.
Speaking about the achievement, Punya Salila Srivastava, Union Health Secretary, stated, "The Central Drugs Standards Control Organisation (CDSCO, in collaboration with WHO, has made exemplary efforts towards this achievement. India is one of the main players in the pharmaceutical industry worldwide and is known for its affordable vaccines and generic medicines.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)